Almotriptan warnings and precautions: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Almotriptan}} {{CMG}}; {{AE}} {{PB}} ==Warnings== ==Precautions== ==References== {{Reflist|2}} Category:AntiMigaraineDrugs Category:Drugs") |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{PB}} | {{CMG}}; {{AE}} {{PB}} | ||
==Warnings | ==Warnings Precautions== | ||
* Serious adverse cardiac events, including [[acute myocardial infarction]] and life-threatening disturbances of [[cardiac rhythm]] | |||
* It is strongly recommended that Almotriptan not be given to patients in whom unrecognized [[coronary artery disease]] (CAD) is predicted by the presence of risk factors. In very rare cases, serious cardiovascular events have been reported in association with Almotriptan use in the absence of known cardiovascular disease. If Almotriptan is considered, patients should first have a cardiovascular evaluation. If the evaluation is satisfactory, first dose should take place in a physician's office setting | |||
* Sensations of pain, tightness, pressure, and heaviness in the chest, throat, neck, and jaw: generally not associated with [[myocardial ischemia]], but patients with signs or symptoms suggestive of angina should be evaluated for the presence of CAD | |||
* Cerebrovascular events, some fatal | |||
* Gastrointestinal ischemic events and peripheral vasospastic reactions (e.g., [[Raynaud's syndrome]]) | |||
* Potentially life-threatening [[serotonin syndrome]], particularly in combination with [[selective serotonin reuptake inhibitors]] ([[SSRIs]]) or [[serotonin norepinephrine reuptake inhibitor]]s ([[SNRI]]s). Monitor patients for neurologic changes and gastrointestinal symptoms if concomitant treatment is clinically warranted | |||
* Increase in blood pressure, very rarely associated with significant clinical events | |||
* Use with caution in patients with a known [[hypersensitivity]] to [[sulfonamides]] | |||
==References== | ==References== | ||
| Line 14: | Line 18: | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Revision as of 02:05, 5 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]
Warnings Precautions
- Serious adverse cardiac events, including acute myocardial infarction and life-threatening disturbances of cardiac rhythm
- It is strongly recommended that Almotriptan not be given to patients in whom unrecognized coronary artery disease (CAD) is predicted by the presence of risk factors. In very rare cases, serious cardiovascular events have been reported in association with Almotriptan use in the absence of known cardiovascular disease. If Almotriptan is considered, patients should first have a cardiovascular evaluation. If the evaluation is satisfactory, first dose should take place in a physician's office setting
- Sensations of pain, tightness, pressure, and heaviness in the chest, throat, neck, and jaw: generally not associated with myocardial ischemia, but patients with signs or symptoms suggestive of angina should be evaluated for the presence of CAD
- Cerebrovascular events, some fatal
- Gastrointestinal ischemic events and peripheral vasospastic reactions (e.g., Raynaud's syndrome)
- Potentially life-threatening serotonin syndrome, particularly in combination with selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs). Monitor patients for neurologic changes and gastrointestinal symptoms if concomitant treatment is clinically warranted
- Increase in blood pressure, very rarely associated with significant clinical events
- Use with caution in patients with a known hypersensitivity to sulfonamides